about
Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective studyAntiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care.Achievement of target blood pressure levels in chronic kidney disease: a salty question?Epidemiology of CKD Regression in Patients under Nephrology Care.Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies.Birth defects in Gaza: prevalence, types, familiarity and correlation with environmental factors.Epidemiology of low-proteinuric chronic kidney disease in renal clinicsAssociations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.Management of hypertension in chronic kidney disease.Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney diseaseModerate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up studyPro: Thresholds to define chronic kidney disease should not be age-dependent.Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.Stage 5-CKD under nephrology care: to dialyze or not to dialyze, that is the question.Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology.A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population.Management of hypertension in patients with CKD: differences between primary and tertiary care settings.Worldwide growing epidemic of CKD: fact or fiction?Resistant hypertension in nondialysis chronic kidney disease.Low-protein diets for chronic kidney disease patients: the Italian experience.Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor.Conversion from epoetin and darbepoetin to C.E.R.A. in non-dialysis CKD patients: a multicenter Italian prospective study in nephrology practice.Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.Letter to the Editor: comment on the article "estimating the influence of physicians on the underuse of drugs in diabetic nephropathy in Taiwan" by Huang et al, and author's reply.Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease.Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study.Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure.Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease: Long-Term Cohort Study.Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy.Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.Effect of post-nephrectomy acute kidney injury on renal outcome: a retrospective long-term study.Intestinal adsorption of uraemic toxins: a new strategy for anaemia management?Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability?Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.Safety and effectiveness of low-protein diet supplemented with ketoacids in diabetic patients with chronic kidney disease.Antiproteinuric response to add-on aliskiren in proteinuric patients treated with dual blockade of the renin-angiotensin system: a 12-month prospective uncontrolled study.Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care.
P50
Q34124770-0EB16753-5BB5-4ED9-931A-F3F7795FF1A9Q34483554-0621C536-8184-431B-B9ED-0E575E38DA93Q35628810-2DC8DA13-34C5-4A8E-BD69-7F06CB22B08CQ35757830-9E93C163-979E-4B59-A400-A8C1199C258FQ35804954-FBFC0A51-A027-4BAC-BCCC-9F2D4B56383EQ35811128-8FBA2B81-614F-49F4-8F13-9C980B7BA4EEQ36067576-2BEE3B70-0A48-4E15-8BD3-D0B68BF1DAA9Q36284146-DB30528F-EEA6-4595-ADCC-86C3DDB8571AQ36543089-58B2901C-2D3E-4690-8589-80AC1FF08F2DQ36670679-68456BAF-F194-410F-BCA2-0E9BA657468FQ37123211-E002D625-B144-41BE-B9B6-C8586B700A76Q37336662-8812B8D2-CE53-4C85-8298-1EB3358DA7D3Q38180634-BCFCE469-20A9-4DA6-BEDE-32B40EF6F859Q38199782-50565487-10C2-4600-ACFE-67B42D4D7F10Q38638777-3286D922-EAA2-43F5-BF7A-C9CDF5C65110Q38939078-67920F8C-7FD3-4D4D-80DD-A7A2CF36D93EQ39130791-0894E5A7-A153-4571-98A0-165829F45BACQ39721678-B0E9C64C-A648-413C-BD0E-20CB27D442AFQ40623799-26BF5498-90AA-4699-A3AE-11E39286700EQ40716454-458EA1E6-9C9D-4EEE-A130-5CAC5FCF396AQ42426578-2312D4B3-EFE2-4870-BE2A-63EA4DD9480EQ42467372-46D59919-8B74-4C6D-9279-F6545FD078B2Q42615996-6C62A6EB-2191-4F07-9014-64E38AA3E82DQ43657220-C144C6DF-6B76-41BA-BD73-CAEDBF980AC8Q43997179-946EF4E0-0762-4B7F-AB1A-AED18113E8D9Q44315893-3745C318-A477-4FD9-8305-8A59BD503BBBQ44445099-D3900C80-AD18-4A23-84E7-6DAB5A6EB903Q44538782-78488069-6593-4CF5-926D-503C8D73F4BAQ44609809-C76E4412-A040-4C29-8AC2-F1B7546FA2EDQ46839434-A839967A-31B9-4E7C-B194-6404E29184DAQ46966698-EA1156B7-E47D-45F7-818D-9B233161F3C4Q48287588-E9F2B316-545B-4934-8FA7-E77546F896E9Q50074126-6730B9C0-FA8A-410D-AA8F-6DAB2602C187Q51738037-848D089C-8E09-4AC0-A37E-266DADAB759DQ53096541-F37EFB6C-45A3-408E-BB4C-6394C7E32684Q53180368-72BC5633-78DF-4C97-AB58-B1F7F52D14B6Q53501050-494F10F0-277E-42A3-A47E-DBC7E23B7900Q53685290-5F89B4D2-F2ED-4B9D-9E06-6FD101E6557FQ53851916-519A22C9-9406-4394-B447-D0C654C445E3Q54306096-199686A5-83FC-4EDA-9DEF-173661521868
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Minutolo
@ast
Roberto Minutolo
@en
Roberto Minutolo
@es
Roberto Minutolo
@nl
Roberto Minutolo
@sl
type
label
Roberto Minutolo
@ast
Roberto Minutolo
@en
Roberto Minutolo
@es
Roberto Minutolo
@nl
Roberto Minutolo
@sl
prefLabel
Roberto Minutolo
@ast
Roberto Minutolo
@en
Roberto Minutolo
@es
Roberto Minutolo
@nl
Roberto Minutolo
@sl
P106
P1153
6603821730
P21
P31
P496
0000-0001-5686-2089